Germany’s Complement Bets On Gene Therapy For Geographic Atrophy
As Series A Raises €72m
Executive Summary
US approval of Apellis's Syfovre has validated the complement approach for treating the advanced stage of age-related macular degeneration but a Munich-headquartered start-up believes its gene therapy will be a more potent and less burdensome alternative.
You may also be interested in...
Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund
Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.
Finance Watch: Q2 Saw Fewer, But Larger, Venture Capital Deals
Private Company Edition: Fewer biotech companies raised venture capital in the second quarter, but the amount of capital raised was on par with the first quarter. Also, former BMS R&D exec Rupert Vessey joined Flagship Pioneering, two new VC funds emerged and Septerna raised a $150m series B round.
Forbion Will Use New Fund To Rescue Struggling Biotechs
The Netherlands and Germany-based VC firm wants to help out public and private companies who have undervalued late-stage assets and are struggling to raise new funds.